Lattice Biologics (TSX-V: LBL) (OTCBB: BLVKF) announced an increase in the size of its non-brokered private placement, from $750,000 to $1.5M in response to high investor demand. As a result, the funding raise will be extended for an additional 30 day period. After the close of the private placement’s third tranche, Lattice issued 2,556,235 units (one unit is equivalent to one common share of capital stock and one-half of one common share purchase warrant) at $0.20CAN each, creating gross proceeds in the sum of $390,000USD. After this latest closing, total investor funding is up to $690,000USD. Proceeds from the placement will…
Browsing: Uncategorized
Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.
DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).
MicroRNA’s are very small endogenous, non-coding, oligonucleotides. They are implicated in regulating a broad range of biological processes. These are molecules which are involved in important regulation of biological processes, and the potential of using these molecules as targets for treatment is becoming ever more apparent. With increased interest from big pharma, it is now important to identify a handful of smallcap companies specializing in this field.
Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
The research division of OneMedPlace has produced a quarterly Investor Guide to Oncology. This guide features our editorial series on innovative technology changing cancer treatment, a directory of the most intriguing companies in the space, and a list of resources. These guides are produced as part of OneMedForum, the bi-annual conference held in San Francisco and New York each year. OneMedForum showcases promising emerging growth companies in this particularly hot sector alongside programming devoted to investment strategy in the space. The 6th Annual OneMedForum will take place January 7-9 in San Francisco. For more information and to register, visit www.onemedforum.com.…